Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 103, Issue 3, Pages 587-592
Publisher
Wiley
Online
2011-12-04
DOI
10.1111/j.1349-7006.2011.02175.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature
- (2011) Prerana Jha et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
- (2011) Ichiyo Shibahara et al. International Journal of Clinical Oncology
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
- (2011) A. L. Rivera et al. NEURO-ONCOLOGY
- 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
- (2011) Genglin Jin et al. PLoS One
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
- (2010) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- Molecular Classification of Low-Grade Diffuse Gliomas
- (2010) Young-Ho Kim et al. AMERICAN JOURNAL OF PATHOLOGY
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
- (2010) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
- (2010) Brock C. Christensen et al. JNCI-Journal of the National Cancer Institute
- Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis
- (2010) J. Laffaire et al. NEURO-ONCOLOGY
- IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
- (2010) C. Houillier et al. NEUROLOGY
- All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
- (2010) M. Labussiere et al. NEUROLOGY
- Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma
- (2009) Andrey Korshunov et al. ACTA NEUROPATHOLOGICA
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
- (2009) Takuya Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- Analysis ofIDH1andIDH2mutations in Japanese glioma patients
- (2009) Yukihiko Sonoda et al. CANCER SCIENCE
- IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
- (2009) S. Nobusawa et al. CLINICAL CANCER RESEARCH
- IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors
- (2009) Fonnet E. Bleeker et al. HUMAN MUTATION
- MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
- (2009) Marc Sanson et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
- (2009) Koichi Ichimura et al. NEURO-ONCOLOGY
- IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
- (2009) H. J. Dubbink et al. NEUROLOGY
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of the IDH1 codon 132 mutation in brain tumors
- (2008) Jörg Balss et al. ACTA NEUROPATHOLOGICA
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started